What's new — Vascular dementia¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 6 |
| last 2 months | 12 |
| last 3 months | 13 |
| last 6 months | 18 |
| last year | 38 |
| older than a year | 393 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-09 | Centrum Semiovale Perivascular Spaces Predict First Hemorrhagic Lesion in Asymptomatic Amyloid-Positive Individuals — Ann Neurol ([PMID 42855813](https://pubmed.ncbi.nlm.nih.gov/42855813/){target="_blank" rel="noopener"}) | cerebral-amyloid-angiopathy |
| 2026-10-06 | Head-to-head comparison of diffusion imaging markers for cognitive decline and risk of dementia: The population-based Rotterdam Study — Imaging Neurosci (Camb) ([PMID 42846338](https://pubmed.ncbi.nlm.nih.gov/42846338/){target="_blank" rel="noopener"}) | neuroimaging |
| 2026-10-05 | Interventions to reduce cognitive decline post-stroke: an umbrella review — Eur Stroke J ([PMID 42886840](https://pubmed.ncbi.nlm.nih.gov/42886840/){target="_blank" rel="noopener"}) | treatment |
| 2026-10-03 | Visual rating versus volumetric segmentation of white matter hyperintensities for cognitive assessment: a memory clinic-based comparison and systematic review — Cereb Circ Cogn Behav ([PMID 42898208](https://pubmed.ncbi.nlm.nih.gov/42898208/){target="_blank" rel="noopener"}) | neuroimaging |
| 2026-10-02 | Dose-response relationship of exercise intervention on cognitive function in patients with stroke: a systematic review and meta-analysis — Top Stroke Rehabil ([PMID 42912759](https://pubmed.ncbi.nlm.nih.gov/42912759/){target="_blank" rel="noopener"}) | treatment |
| 2026-10-02 | Neuropsychiatric symptoms in vascular cognitive impairment: A comparative study between CADASIL and sporadic small vessel disease — J Formos Med Assoc ([PMID 42907303](https://pubmed.ncbi.nlm.nih.gov/42907303/){target="_blank" rel="noopener"}) | cognitive-profile-and-assessment, monogenic-and-inherited-forms |
| 2026-10-01 | Location matters: Attributing cognitive symptoms to white matter hyperintensities in 3,481 memory clinic patients — Dement Geriatr Cogn Disord ([PMID 42895925](https://pubmed.ncbi.nlm.nih.gov/42895925/){target="_blank" rel="noopener"}) | neuroimaging, subtypes-and-clinical-syndromes |
| 2026-10-01 | Vascular dementia and vascular cognitive impairment-current treatments and future prospects — Int J Stroke ([PMID 42894468](https://pubmed.ncbi.nlm.nih.gov/42894468/){target="_blank" rel="noopener"}) | treatment |
| 2026-10-01 | Pericyte loss and endothelial activation define distinct vascular states in cerebral small vessel disease — Acta Neuropathol ([PMID 42867637](https://pubmed.ncbi.nlm.nih.gov/42867637/){target="_blank" rel="noopener"}) | pathophysiology |
| 2026-10-01 | Longitudinal associations between physical activity and cognition post-stroke: the Nor-COAST study — Brain Commun ([PMID 42865713](https://pubmed.ncbi.nlm.nih.gov/42865713/){target="_blank" rel="noopener"}) | treatment |
| 2026-09-02 | Interaction Between Age and the NOTCH3 p.R544C Variant in Determining Ischemic Stroke Risk: Insights from the Taiwan Biobank Study of 8,588 Patients — Int J Med Sci ([PMID 42910061](https://pubmed.ncbi.nlm.nih.gov/42910061/){target="_blank" rel="noopener"}) | monogenic-and-inherited-forms |
| 2026-09-02 | Reconsideration of the DTI-ALPS index as a glymphatic surrogate: disease-specific findings in small vessel disease due to cerebral amyloid angiopathy or arteriolosclerosis — Front Aging Neurosci ([PMID 42840269](https://pubmed.ncbi.nlm.nih.gov/42840269/){target="_blank" rel="noopener"}) | cerebral-small-vessel-disease |
| 2026-08-02 | Pharmacological interventions targeting cognition and related clinical outcomes in vascular dementia: a systematic review and meta-analysis of randomized controlled trials — Eur J Clin Pharmacol ([PMID 42635820](https://pubmed.ncbi.nlm.nih.gov/42635820/){target="_blank" rel="noopener"}) | overview, treatment |
| 2026-08-01 | Intensive versus standard blood pressure control and overall brain small vessel disease burden: a post-hoc analysis of the SPRINT randomized clinical trial — EClinicalMedicine ([PMID 42614618](https://pubmed.ncbi.nlm.nih.gov/42614618/){target="_blank" rel="noopener"}) | clinical-trials-landscape, overview, prevention-and-risk-factor-control |
| 2026-07-03 | Isosorbide Mononitrate/Cilostazol for Lacunar Cerebral Small Vessel Disease-Outcomes at 6 Months in the LACI-2 Randomized Controlled Trial — J Am Heart Assoc ([PMID 42535538](https://pubmed.ncbi.nlm.nih.gov/42535538/){target="_blank" rel="noopener"}) | treatment |
| 2026-07-01 | Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial — Lancet ([PMID 42442374](https://pubmed.ncbi.nlm.nih.gov/42442374/){target="_blank" rel="noopener"}) | prevention-and-risk-factor-control |
| 2026-06-02 | Physician Approaches to Determining Goals of Stroke Care for Patients Living With Disability or Dementia: Results from the SEED Mixed-Methods Study — Stroke ([PMID 42339544](https://pubmed.ncbi.nlm.nih.gov/42339544/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-06-01 | Differential associations of plasma biomarkers with Alzheimer's disease and small vessel disease: A multimodal imaging study — Alzheimers Dement ([PMID 42252508](https://pubmed.ncbi.nlm.nih.gov/42252508/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-05-01 | Effects of Exercise and Intensive Vascular Risk Reduction on Cognitive Function in Older Adults: A Randomized Clinical Trial — JAMA Neurol ([PMID 41870419](https://pubmed.ncbi.nlm.nih.gov/41870419/){target="_blank" rel="noopener"}) | clinical-trials-landscape, prevention-and-risk-factor-control |
| 2026-04-09 | MRI evaluation of cerebral perivascular spaces predicts amyloid-related imaging abnormalities risk in preclinical Alzheimer's disease — Front Dement ([PMID 42040755](https://pubmed.ncbi.nlm.nih.gov/42040755/){target="_blank" rel="noopener"}) | cerebral-amyloid-angiopathy |
| 2026-04-02 | Impact of Different Antihypertensive Drug Classes on Incident Dementia in Older Adults: A Systematic Review and Meta-Analysis — J Am Med Dir Assoc ([PMID 41962914](https://pubmed.ncbi.nlm.nih.gov/41962914/){target="_blank" rel="noopener"}) | prevention-and-risk-factor-control |
| 2026-04-02 | Incidence and prevalence of vascular cognitive impairment in China: a systematic review and meta-analysis — Stroke Vasc Neurol ([PMID 40889799](https://pubmed.ncbi.nlm.nih.gov/40889799/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-03-04 | Multidomain post-stroke cognitive impairment: development and validation of a clinical prediction model — Lancet Healthy Longev ([PMID 41794047](https://pubmed.ncbi.nlm.nih.gov/41794047/){target="_blank" rel="noopener"}) | cognitive-profile-and-assessment |
| 2026-03-01 | Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial — Alzheimers Dement ([PMID 41795685](https://pubmed.ncbi.nlm.nih.gov/41795685/){target="_blank" rel="noopener"}) | treatment |
| 2026-03-01 | Estimating the costs of informal care for individuals with brain health disorders from 2000 to 2021: a modelling study — Lancet Public Health ([PMID 41748237](https://pubmed.ncbi.nlm.nih.gov/41748237/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-02-05 | Ginkgo biloba for cognitive impairment and dementia — Cochrane Database Syst Rev ([PMID 41641880](https://pubmed.ncbi.nlm.nih.gov/41641880/){target="_blank" rel="noopener"}) | guidelines, overview, treatment |
| 2026-02-01 | Post-stroke cognitive impairment is associated with poorer return-to-work outcomes in working-aged stroke survivors: A systematic review — Clin Rehabil ([PMID 41666123](https://pubmed.ncbi.nlm.nih.gov/41666123/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-02-01 | Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer's disease in a diverse cohort: MESA — Alzheimers Dement ([PMID 41630612](https://pubmed.ncbi.nlm.nih.gov/41630612/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-01-02 | Multimodal Magnetic Resonance Imaging Signatures of White Matter Hyperintensities: Mechanistic Insights Into Pathobiological Heterogeneity — J Stroke ([PMID 41656632](https://pubmed.ncbi.nlm.nih.gov/41656632/){target="_blank" rel="noopener"}) | pathophysiology |
| 2026-01-02 | Neuropathologic Profiles and Associated Cognitive Trajectories in Community-Living Older Adults — JAMA Netw Open ([PMID 41543852](https://pubmed.ncbi.nlm.nih.gov/41543852/){target="_blank" rel="noopener"}) | mixed-pathology-and-alzheimer-overlap |
| 2026-01-01 | Development of a Prognostic Model for Poststroke Dementia Using Multiple International Cohorts: A STROKOG Collaboration Study — Neurology ([PMID 41525568](https://pubmed.ncbi.nlm.nih.gov/41525568/){target="_blank" rel="noopener"}) | post-stroke-cognitive-impairment |
| 2025-12-03 | Efficacy and safety of antihypertensive drugs deprescribing in older adults: A systematic review and meta-analysis of randomized controlled trials — Int J Cardiol Cardiovasc Risk Prev ([PMID 41550131](https://pubmed.ncbi.nlm.nih.gov/41550131/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2025-12-02 | Association of Plasma GFAP and NfL in Middle-Aged Adults With MRI Markers of Cerebral Small Vessel Disease Later in Life — Neurology ([PMID 41461058](https://pubmed.ncbi.nlm.nih.gov/41461058/){target="_blank" rel="noopener"}) | biomarkers |
| 2025-12-01 | Network meta-analysis of the efficacy of pharmacological treatments for post-stroke cognitive impairment and vascular cognitive impairment — Front Neurol ([PMID 41404461](https://pubmed.ncbi.nlm.nih.gov/41404461/){target="_blank" rel="noopener"}) | treatment |
| 2025-11-06 | Neuroimaging Markers Associated With Recurrent Stroke in Intracerebral Hemorrhage and Atrial Fibrillation: Secondary Analysis of PRESTIGE-AF — Neurology ([PMID 41197104](https://pubmed.ncbi.nlm.nih.gov/41197104/){target="_blank" rel="noopener"}) | cerebral-amyloid-angiopathy |
| 2025-11-04 | Synergistic effect between cortical cerebral microinfarcts and brain atrophy on cognitive decline — Brain ([PMID 40796328](https://pubmed.ncbi.nlm.nih.gov/40796328/){target="_blank" rel="noopener"}) | neuroimaging |
| 2025-11-02 | Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial — J Psychopharmacol ([PMID 41277041](https://pubmed.ncbi.nlm.nih.gov/41277041/){target="_blank" rel="noopener"}) | treatment |
| 2025-11-01 | Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia-The VasCog-2-WSO Criteria — JAMA Neurol ([PMID 40955506](https://pubmed.ncbi.nlm.nih.gov/40955506/){target="_blank" rel="noopener"}) | guidelines, nosology-and-diagnostic-criteria, overview |
Trials — what has moved¶
48 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 2 |
| trial records updated in the last month | 6 |
| trial records updated in the last 2 months | 8 |
| trial records updated in the last 3 months | 10 |
| trial records updated in the last 6 months | 12 |
| trial records updated in the last year | 20 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2024-11-12 | LACunar Intervention (LACI-2) Trial-2 | PHASE2, PHASE3 | 363 | Feasibility of Phase III Trial | 77 | 0 | 3 |
| 2021-02-23 | Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of M | PHASE3 | 276 | Percentage of Patients With Improved Cognitive Function (The Montreal | 7 | 76 | 1 |
| 2017-12-04 | Systolic Blood Pressure Intervention Trial | NA | 9361 | Number of Participants With First Occurrence of a Myocardial Infarctio | 3529 | 2741 | 365 |
26 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| cerebral-amyloid-angiopathy | 2026-10-09 | 3 | 34 |
| neuroimaging | 2026-10-06 | 4 | 33 |
| treatment | 2026-10-05 | 10 | 47 |
| cognitive-profile-and-assessment | 2026-10-02 | 2 | 28 |
| monogenic-and-inherited-forms | 2026-10-02 | 2 | 34 |
| pathophysiology | 2026-10-01 | 2 | 33 |
| subtypes-and-clinical-syndromes | 2026-10-01 | 1 | 32 |
| cerebral-small-vessel-disease | 2026-09-02 | 1 | 40 |
| overview | 2026-08-02 | 4 | 57 |
| clinical-trials-landscape | 2026-08-01 | 2 | 29 |
| prevention-and-risk-factor-control | 2026-08-01 | 4 | 36 |
| patient-experience-and-advocacy | 2026-06-02 | 2 | 27 |
| biomarkers | 2026-06-01 | 3 | 33 |
| epidemiology-and-burden | 2026-04-02 | 2 | 31 |
| guidelines | 2026-02-05 | 2 | 28 |
| mixed-pathology-and-alzheimer-overlap | 2026-01-02 | 1 | 27 |
| post-stroke-cognitive-impairment | 2026-01-01 | 1 | 29 |
| red-flags-and-safety-concerns | 2025-12-03 | 1 | 30 |
| nosology-and-diagnostic-criteria | 2025-11-01 | 1 | 36 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.